Anti-idiotypic antibodies in patients with different clinical forms of paracoccidioidomycosis

A R Souza1, J L Gesztesi, G M del Negro

  • 1Discipline of Immunology, Federal University of São Paulo (UNIFESP), São Paulo Brazil.

Insights

Anti-idiotypic (anti-Id) antibodies (Ab2) were found in all Paracoccidioidomycosis (PCM) patients. High Ab2 titers correlated with acute PCM, while lower titers were seen in chronic forms, suggesting Ab2 levels indicate disease severity.

Area of Science:

  • Mycology
  • Immunology
  • Infectious Diseases

Background:

  • Paracoccidioidomycosis (PCM) is a prevalent systemic mycosis in Latin America with diverse clinical presentations.
  • The major parasitic antigen is a 43 kDa glycoprotein (gp43), against which patients develop anti-gp43 antibodies.
  • Spontaneous anti-idiotypic (anti-Id) antibodies (Ab2) are detected in PCM patients with high anti-gp43 titers.

Purpose of the Study:

  • To purify and characterize anti-Id antibodies in the context of Paracoccidioidomycosis.
  • To investigate the potential correlation between Ab2 titers and different clinical forms of PCM.
  • To assess the relationship between Ab2 levels and disease severity.

Main Methods:

  • Purification of human anti-Id antibodies from patient sera.
  • Characterization of anti-Id antibody recognition of specific murine monoclonal anti-gp43 antibodies.
  • Quantification of Ab2 titers in patients across acute and chronic PCM forms.

Main Results:

  • Purified human anti-Id antibodies specifically recognized certain murine anti-gp43 monoclonal antibodies.
  • Spontaneous anti-Id antibodies were present in all PCM clinical forms.
  • High Ab2 titers were found in 88% of acute PCM patients, contrasting with 29% in multifocal chronic and low titers in 70% of unifocal chronic forms.

Conclusions:

  • Anti-Id antibody titers demonstrate a correlation with the clinical forms and severity of Paracoccidioidomycosis.
  • Ab2 levels may serve as a potential biomarker for monitoring PCM disease progression and treatment response.